A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)
The purpose of this study is to explore the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of INCB024360 administered in combination with MEDI4736 in subjects with selected advanced solid tumors.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Jan 13, 2022 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Incyte Corporation
- Interventions being studied
- Drug: MEDI4736; Drug: INCB024360
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Male or female subjects, age 18 years or older
- Histologically or cytologically confirmed diagnosis of selected locally advanced or metastatic solid tumors
- Must have failed at least 1 prior treatment regimen for locally advanced or metastatic disease or be intolerant to treatment or refuse standard treatment
- Laboratory and medical history parameters not within protocol-defined range
- Participation in any other study in which receipt of an investigational study drug occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose
- Prior treatment with immune checkpoint inhibitors (eg, anti-CTLA-4, anti-PD-1, anti-PD-L1, and any other antibody or drug specifically targeting T-cell co-stimulation) or an IDO inhibitor (exception is tumor types in which a PD-1 pathway targeted agent is approved, e.g. melanoma, non-small cell lung cancer.)
- Receipt of any anticancer medication in the 21 days prior to receiving the first dose of study medication
- Has an active or inactive autoimmune process
- Evidence of interstitial lung disease or active, non-infectious pneumonitis
- Prior radiotherapy within 2 weeks of initiating treatment; Must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
- Untreated central nervous system (CNS) metastases or CNS metastases that have progressed
- Currently pregnant or breastfeeding
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Study locationSan Francisco, California
- Study locationDenver, Colorado
- Study locationMiami, Florida
- Study locationPort Saint Lucie, Florida
- Study locationSarasota, Florida
- Study locationTampa, Florida
- Study locationChicago, Illinois
- Study locationLouisville, Kentucky
- Study locationDurham, North Carolina
- Study locationHuntersville, North Carolina
- Study locationWinston-Salem, North Carolina
- Study locationDallas, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 13, 2022. Always confirm current availability with the study team.